Cell saver efficacy for routine coronary artery bypass surgery

Area of Science:

• Cardiovascular Surgery
• Transfusion Medicine
• Anesthesiology

Background:

• The Haemonetics Cell Saver (HCS) is a device used for intraoperative autologous blood recovery.
• Its effectiveness in reducing homologous blood product transfusion in Coronary Artery Bypass Grafting (CABG) surgery requires further investigation, especially in the context of modern blood conservation efforts.

Purpose of the Study:

• To evaluate the impact of intraoperative Haemonetics Cell Saver (HCS) usage on postoperative homologous blood product requirements in patients undergoing elective, first-time CABG surgery.

Main Methods:

• A retrospective study compared 435 CABG patients who received HCS (Group CS) with 81 patients who did not (Group NCS).
• Patients with renal disease or significant postoperative bleeding were excluded.
• Transfusion data for red blood cells (RBC), fresh frozen plasma (FFP), and platelets (PLTS) were analyzed and compared between the two groups.

Main Results:

• No significant differences were observed in the mean units of RBC, FFP, or PLTS transfused per patient between the HCS and no-HCS groups.
• Transfusion rates for RBCs (48% vs. 50%) and the percentage of patients receiving FFP or PLTS (12% vs. 8%) were similar in both groups.
• The study found no evidence that HCS usage decreased the need for postoperative homologous blood products.

Conclusions:

• Intraoperative cell salvage using the Haemonetics Cell Saver does not appear to reduce the requirement for homologous blood products in patients undergoing routine, first-time CABG surgery.
• Current aggressive blood conservation strategies may diminish the perceived benefit of cell saver technology in this patient population.